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Abstract 
This small cohort study was conducted to determine, by way of contrast-enhanced ultrasound (CEUS), if 
there is a quantifiable vascular difference in patients affected with carpal tunnel syndrome (CTS) symptoms versus 
patients who are not affected by the disease’s symptoms. The clinical translation of this study was to identify CEUS 
as a novel diagnostic tool for the detection and evaluation of CTS and encourage the FDA approval of CEUS studies 
in the U.S. medical field. 
Ultrasound equipment settings and dosing were optimized to provide consistent CEUS imaging.  The 
contrast dosing amounts were determined at the discretion of the lead echo sonographer and varied in both 
dosing amount and number of dosing injections.  UCA dosing amounts varied from 3 ml (Patient 1) to 5 ml (Patient 
5), with a mean dose of 3.33 ml over all patients.  The contrast solution for all subjects contained 1.3 ml of 
Definity® to 8.7 ml of saline.  In addition, the equipment parameters were maintained at 4% output power and a 
mechanical index (MI) of 0.13.  The transmit frequency of the linear transducer was held at a constant of 9 MHz 
throughout the trials. 
The use of an image analysis software program was employed to quantiitize the amount of perinueral 
vascularity. An interclass correlation coefficient (ICC) was calculated between the investigators for manual signal 
counts and Iavg within the ROI to determine user reliability.  Chronbach’s alpha for signal counts and Iavg were 
0.90 and 0.80 and ICCs were 0.90 (p< 0.01) and 0.80 (p<0.01), respectively. 
This clinical study confirmed successful equipment settings and image analysis that allowed for a valid and 
reliable demonstration of vascularity surrounding the human median nerve; furthermore, the study found a 
qualitative difference in the vascularity of asymptomatic versus symptomatic median nerves.   
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Chapter 1 – Introduction 
Background 
 Carpal tunnel syndrome (CTS) is a collection of characteristic symptoms and signs that occur following 
entrapment of the median nerve within the carpal tunnel.  CTS is the most commonly reported nerve entrapment 
syndrome, as well as the most common work-related musculoskeletal disorder.  Despite the large number of 
original research studies on CTS, considerable uncertainty exists about its extent and etiology, the contribution of 
work and non-work risk factors to its development, the criteria used to diagnose it, the outcomes of various 
treatment methods, and the appropriate strategies for intervention and prevention.
1
 The only certainties of the 
disease are the subsequent pathophysiology of the entrapped median nerve and resultant CTS, as well as the 
syndrome’s alarmingly increased incidence rate across the globe. 
 The epidemiology of carpal tunnel syndrome has been reported in general populations; mainly in specific 
regional, national groups, or in working populations related to workers’ compensation claims.  Studies in the 
Netherlands, Italy, and in the United States have focused on single cities or regions and have noted incidence rates 
from 1.3 to 3.5 per 1,000 person-years.
2-3
  Korea has been documented to have the highest prevalence, with a rate 
of 4.96 per 1,000 person-years.
3
  Other demographic studies have shown a higher incidence of carpal tunnel 
syndrome in working populations and employees of at-risk occupations, consistent with data showing that 
repetitive motion of the wrist may be contributory to the symptoms of CTS.
4
  Diagnostic Medical Sonographers 
(DMS) are model examples of workers in an at-risk occupation, as studies have indicated that approximately 65% 
of DMS have experienced CTS symptoms throughout their career and over 90% are working in pain.
5
   
 Frequent or repeated compression and stress on the median nerve creates a constellation of pathological 
symptoms, with the eventual outcome of CTS.  The initial insult of median nerve entrapment is a reduction in 
epinueral blood flow, caused by the elevated pressure and stress.  This impaired nerve perfusion triggers ischemia 
and damage to the nerve-blood barrier within the endoneurial capillaries.  Continued or increased pressure 
eventually causes epineural edema and inflammation, with the inflammation resulting in fibrosis.  The effects of 
2 
   
perineural fibrosis lead to scar tissue formation, axonal injury, and localized demyelination.
6-8
  This pathological 
cascade of CTS symptoms result in physiological symptoms surrounding the affected nerve, and increase in 
severity as the individual’s CTS progresses.  Early clinical symptoms include intermittent numbness, tingling, 
burning, or pain in the lateral palm, thumb, index, and middle fingers.  The hallmark symptom of CTS is nocturnal 
pain and numbness, often causing affected individuals to be awaken at night.  Clinical symptoms increase in 
severity as the syndrome progresses; which leads to paresthesia, the inability to grip or pinch, constant numbness, 
and decreased pain due to nerve demyelination.  At the most advanced stage of CTS, the affected individual may 
experience muscle atrophy and increased weakness.
7-8
 
  Diagnostic procedures for carpal tunnel syndrome remain largely inconsistent to-date, mainly due to a 
lack of a “gold standard” test for the syndrome.   Diagnoses often rely on an assemblage of testing procedures that 
vary from clinical evaluations and elecrodiagnostic studies (EDX), to the recently novel sonographic examinations 
(US).  Clinical diagnoses include an extensive examination of symptom specifics:   including location, 
characteristics, provocative factors, and functional status surveys (FSS) or symptom severity surveys (SSS).
9
  
Physical testing is often utilized for clinical diagnosis with the help of a myriad of subjective testing, including but 
not limited to Phalen’s test, Tinel sign, Durkin’s test, carpal tunnel compression test (with and without wrist 
flexion), and a hand elevation test.  Electrodiagnostic studies (EDX) include electromyography (EMG) and nerve 
conduction studies (NCS), with NCS more commonly used.
7
 While EDX has previously been considered a “gold 
standard” for entrapment neuropathy diagnosis, its true significance has recently been debated within the 
research literature.
10-13
  Imaging studies, including sonography, MRI, and CT, have recently been incorporated as a 
novel diagnostic tool.   
The treatment of carpal tunnel syndrome varies and is determined by the severity of the disease.  
Nonoperative management includes splinting the wrist, oral medications, or corticosteroid injection into the carpal 
canal.  These conservative treatments help to reduce associated pain and may completely relieve CTS symptoms.  
However, when nonoperative management fails, surgical treatment is indicated.  Carpal tunnel surgery involves 
the division of the transverse carpal tunnel ligament to alleviate compression of the median nerve, and may be 
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performed openly or endoscopically.  The most common surgery performed is endoscopic carpal tunnel release, 
which has provided excellent success rates.
7 
 In rare cases, some patients may continue to have persistent CTS 
symptoms even after operative procedures, and may require additional evaluation.
6,7
 
Significance of the Problem & Clinical Translation 
 Carpel tunnel syndrome risk and occurrence are ever-increasing in today’s population.  Diabetes, obesity, 
and occupational injuries are several of the contributing factors expected to increase the prevalence rate of CTS.
7,9
  
Consequently, the current trends of carpal tunnel syndrome identify the need for a reliable, non-invasive method 
for evaluating and diagnosing CTS.  The lack of a “gold standard” testing procedure for such a common syndrome is 
becoming increasingly elusive in medicine. While clinical diagnosis and confirmatory EDX provides some form of 
CTS identification, this combination of testing procedures lacks both patient comfort and consistency.  
Electrodiagnostic studies are invasive, uncomfortable, time-consuming, and costly.  Most significantly, the results 
of EDX studies are highly questionable, often producing false-positives and a wide range of sensitivities.
14-15
 
 Fortunately, sonography has presented itself as an exciting, novel diagnostic test for the diagnosis of 
carpal tunnel syndrome.  This modality is widely available throughout the world and provides a cost-efficient, 
portable, and easily tolerable testing alternative.  Additionally, the non-invasive nature and lack of radiation makes 
sonography an ideal testing procedure for repeat examinations.  Current research literature has reported the 
sonographic evaluation of the cross sectional area (CSA) of the median nerve as beneficial for assessing CTS, and a 
recently published study concluded that there was a significant agreement between US and NCS when using a 
combination of sonographic and clinical parameters.
9
  To-date, researchers at The Ohio State University have 
begun to establish a reliable and valid imaging protocol for identifying and measuring the hypervascularity of 
median nerves in symptomatic CTS patients by use of contrast-enhanced ultrasound.
13
  It is plausible that, with 
increasingly supportive data from current and upcoming research trials, sonography may replace EDX as a first-line 
test to confirm clinically diagnosed CTS, and may potentially provide for a “gold standard” in carpel tunnel 
syndrome diagnosis. 
4 
 
Research Objective 
Recent research has not only provided exciting new evidence that sonography may be used in the 
identification and evaluation of CTS, but also supports the idea that sonography may become the “gold standard” 
for the detection and diagnosis for carpal tunnel syndrome.   The modality has already provided definite evidence 
for the subjective and objective detection of the pathological effects observed in CTS patients.
9
  Furthermore, 
clinical studies have shown that contrast-enhanced ultrasound (CEUS) plays an important role in providing a 
quantifiable CTS diagnosis.
13
 Ultrasonic contrast, coupled with perfusion software evaluation, has the logical 
potential to detect the perinueral trauma and associated hypervascularity of the symptomatic entrapped median 
nerve.   
Before implementing the use of sonography as a first-line diagnostic tool for carpel tunnel syndrome, and 
confidently deeming the modality as a “gold standard”, the use of CEUS for evaluating CTS must be further 
explored.  Specifically, appropriate sonography equipment settings and a definite protocol must be identified to 
provide consistent and replicable CEUS images of the median nerve.  Additionally, a quantifiable and irrefutable 
vascular difference in the median nerve must be determined for asymptomatic CTS individuals versus symptomatic 
CTS individuals.  By assessing and determining these central variables, sonography may prove its ability to provide 
a definitive and preferred testing procedure for the diagnosis of CTS.   
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Chapter 2 – Literature Review 
Introduction 
 As stated previously, the use of sonography as a diagnostic tool for carpel tunnel syndrome has become 
an increasingly researched proposal.  Thus far, numerous clinical studies have published conclusions surrounding 
the potential of sonography as a diagnostic tool for the symptomatic median nerve.
9-15
   Subjective sonographic 
differences between affected and unaffected CTS patients have been definitively established, and a significant 
agreement between sonography and NCS parameters has been readily identified in the literature.
9,14-15
  In addition, 
the use of CEUS is possibly the most novel and promising verification of the diagnostic tool, providing 
sonographically quantifiable measurements of pathological CTS symptoms.  The only limitation currently restricting 
the further advancement of CEUS’ diagnostic ability for carpel tunnel syndrome within the United States medical 
field is the lack of the Food and Drug Administration (FDA) approval for the use of ultrasonic contrast agents in the 
United States.  This challenging drawback and its associated implications are further explained in the literature 
below. 
`Contrast-Enhanced Ultrasound (CEUS) 
Throughout the past several years there have been extraordinary advancements regarding contrast-
enhanced ultrasound (CEUS) and its potential abilities.  The use of CEUS has provided the remarkable ability to 
improve sonographic image quality and increase the transmission of the ultrasonic beam.
16 
 Numerous animal and 
human-model studies have been conducted to explore and determine the benefits of CEUS, with Europe and Asia 
undoubtedly pioneering its use. 
Nearly all of the 900 original investigative articles found in PubMed under the search term “Contrast 
Enhanced Ultrasound” are studies from European or Eastern hemisphere countries.
16
  In fact, the first four articles 
examined within this chapter have been written outside the United States – Switzerland, Canada, Japan, and The 
Netherlands, respectively.  Limited studies have been conducted in the United States due to the lack of the U.S. 
Food and Drug Administration (FDA) approval of CEUS, with the exception of cardiac echo studies.
17
  Europe’s 
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extensive lead in the study of CEUS has led to the European Federation of Societies for Ultrasound in Medicine and 
Biology (EFSUMB) to release the first guideline on the use of contrast-enhanced ultrasound.
17
  There have been 
two subsequent guidelines written- with the most recent update of the guideline published online in 2011. 
The purpose of this review was to explore the published results of CEUS nationally and internationally – 
and to highlight any gaps that may exist in our understanding of how contrast media could increase diagnostic 
detection in the U.S., especially in the case of carpal tunnel syndrome. The following articles were reviewed to 
provide evidence for the exciting prospect of ultrasonic contrast agents in diagnostic sonography, and to 
accelerate the FDA’s approval of CEUS outside of echocardiography studies – ultimately leading to the approval of 
CEUS as a supported diagnostic tool for the detection of carpal tunnel syndrome.   
Literature 
Myocardial perfusion imaging, a new advancement in echocardiography, is one new procedure in the field of 
contrast-enhanced ultrasound.
18
  In myocardial contrast echography, minute microbubbles are injected 
intravenously and travel through the coronary microcirculation to produce an opacification of the myocardium.
18
  
Researchers from Bracco Research SA in Geneva, Switzerland developed a study to evaluate the potential of 
SonoVue, a new echo contrast agent, for the detection of myocardial perfusion abnormalities in minipigs. 
Five animal-model experiments were performed in closed-chest minipigs and two were performed in open-
chest minipigs.  The animals were placed under general anesthesia and injected intravenously with the ultrasonic 
contrast agent (UCA) SonoVue (2.5 µm).  Dose range of the UCA varied between 0.01-0.05 mL/kg.  Myocardial 
contrast echography was performed in all experiments using an HDI 3000 ultrasonongraphy machine with 
intermittent harmonic power Doppler.  All machine settings were kept constant throughout each experiment 
except for the pulse repetition frequency (PRF); which ranged between 500 to 6000 Hz. 
Results confirmed that injection of SonoVue caused reproducible and homogenous myocardial opacification at 
0.01 mL/kg.
18
  As the dose of echo contrast increased, a slight increase in peak intensity and a prolongation of the 
myocardial contrast effect was noted
18
.  Specifically, the duration improved from 80 seconds at 0.01 mL/kg to 
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more than 2 minutes at 0.05 mL/kg.  However, doses of 0.03 mL/kg and higher resulted with shadowing within the 
left ventricular cavity.
18
  SonoVue provided differentiation of the ischemic zone from normally perfused zones in 
the left anterior descending aspect of the coronary artery.
18
  The mean myocardial contrast intensity was also 
found to increase when amplifying the pulse repetition frequencies from 500 Hz to 1500 Hz, and reached plateau 
at 1500 Hz.
18
  
Researchers concluded that echo contrast agents, specifically the use of SonoVue, are capable of consistent 
and prolonged enhancement of the myocardium after intravenous injection.
18
  Harmonic Doppler imaging and 
varying PRFs were also determined by the research to enhance the effects of UCAs.
18
 
Previous placental studies detailed the development of the intervillous space- a blood-filled compartment 
which enables effective exchange between fetal and maternal circulations.
19
  Researchers at St. James’s University 
Hospital in Leeds, UK, developed an animal-model series of case studies to evaluate the intervillous flow in early 
pregnancies with the use of echo-enhancement agents.
19
  Using a high-resolution ultrasound scanner, the 
uteroplacental circulation of the cynomolgus monkey (Macaca fascicularis) was examined.  This study similarly 
followed the potential of using UCAs.  The contrast agent, Albunex, was injected intravenously and used to 
enhance the color Doppler images acquired.  Intervillous flow in the macaque was explored to decide whether the 
use of echo-contrast agents would assist in determining placental circulation in human pregnancy at a 
correspondingly early stage.
18
 
Nine cynomolgus monkeys were selected for the study and divided into two groups.  The first group consisted 
of four animals with gestational ages of 18, 27, 31, and 52 days post-conception, respectively.
18
  The second group 
had five animals between 37 and 69 days of gestation.
18
  All studies were performed with an Acuson 128/XP10 
high-resolution ultrasound scanner and completed using a 7-MHz linear array probe with color and pulsed-wave 
Doppler capabilities.  Albunex was the chosen UCA due to its small diameter characteristic.
18
  For a closer 
examination of various microbubble characteristics, please refer to Table 1.   
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Each animal was restrained without sedation during the beginning of the sonographic examination.  Fetal 
viability and biometry were first observed, imaging the uterus in both transverse and sagittal planes.  After 
sedation, placental location was confirmed and uteroplacental vasculature was assessed. Albunex (3.8 µm 0.5 
ml/kg) was then injected intravenously and all gray-scale, color, and pulsed-wave Doppler images were recorded.
19
 
 Results determined that the passage of the spiral arteries at the decidualtrophoblastic interface, and their 
point of discharge into the intracotyledonary space, was clearly identified with the use of color Doppler in the 
macaque at 52 days gestation.
19
  Blood flow analysis of the pulsed-wave Doppler images also revealed the 
characteristic features of flow velocity in the intracotyldonary space.
19
  Venous drainage of the intervillous 
compartment was also visualized in the macaque at 31 days post-conception.
19
  
The authors concluded that intervillous flow in early primate pregnancy can be determined with the use of an 
echo-enhancement agent and pulsed-wave Doppler strategies.
19
  Similar approaches may assist analysis of the 
early intervillous compartment in human pregnancy.
19
 
Sonography has been used as a routine procedure for the detection of focal splenic lesions.
20
  Determinations 
of benignity or malignancy in canine splenic lesions have traditionally been difficult when using conventional 
sonography methods.
20
  Researchers at the Laboratory of Veterinary Internal Medicine replicated previous 
research by exploring whether contrast-enhanced U/S could assist in differentiation between benign and 
malignant focal splenic lesions in dogs.
20
 
Twenty-nine focal splenic lesions were examined in 29 dogs.  Focal splenic lesions in the animals were 
determined by conventional sonography and the final diagnosis was confirmed by histology or cytology.
20
  All 
examinations were performed with an ultrasound machine and a 5-11 MHz broadband linear probe or a 3.75 MHz 
convex probe. 
Perflubutane microbubbles (0.12 µL microbubbles/kg) were injected intravenously within the cephalic vein.
20
  
Real-time imaging was performed from preinjection to 1 minute after injection of the contrast during the vascular 
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phases.  Images during the parenchymal phase were obtained from a previous study, with duration of 7-10 
minutes after injection of the contrast.  
Qualitative assessment of vessel appearance in the lesion was performed immediately after injection.  Vessel 
appearance was divided into 3 groups to compare the vessel with surrounding parenchyma:  similar, different, and 
invisible.  Qualitative assessment of the enhancement pattern was performed in the early vascular phase (5-10 
seconds after injection), late vascular phase (25-30 seconds after injection), and parenchymal phase (7-10 minutes 
after injection).
20
  Enhancement pattern was divided subjectively based on the echogenicity comparison between 
lesion parenchyma and the surrounding normal parenchyma (hypoechoic, isoechoic, and heteroechoic).  Statistical 
analyses determined a significance between benign and malignant lesions and the respective sensitivity and 
specificity.
20
 
Of the 29 dogs included in the study, 13 dogs had benign nodules and 16 dogs had malignant tumors.  The 
vessel appearance was not significantly different between malignant and benign lesions.
20
  However, similar 
patterns were visible in 9 of the 16 malignant lesions and 10 of the 13 benign lesions.
20
  Enhancement patterns 
between benign and malignant lesions were found to be significantly different during the early and late vascular 
phases.
20
  Hypoechoic pattern was found to be significantly associated with malignancy, as a hypoechoic pattern 
was found in 6 of the 16 malignant lesions and in none of the 13 benign lesions.
20
  Isoechoic and heteroechoic 
patterns were not found to be significantly different during the early vascular phase.
20
  In the late vascular phase, 
hypoechoic pattern was significantly associated with malignancy and isoechoic pattern significantly associated with 
benignancy.
20
  No significant difference was found between benign and malignant lesions in the parenchymal 
phase.
20
  
The study concluded that the use of CEUS has significant value in differentiating between benign and 
malignant focal splenic nodules in dogs with high accuracy.
20
  While the parenchymal phase of imaging was not 
significant in differing between benign and malignant lesions, detection of hypoechoic nodules in the late vascular 
phase of perflubutane microbubbles-enhanced ultrasound is suggestive of benign lesions.
20
  Also, differentiation 
between benign and malignant lesions was determined to be highly accurate during the early vascular phase.
20
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Prostatic cancer is the 2
nd
 leading cause of death among males in the United States.
21
  This increased incidence 
sparked the advent of prostate-specific antigen (PSA) assessment and transrectal ultrasound imaging for prostate 
cancer detection.
21
  Further diagnostic advancements resulted with researchers from the University Hospital 
Nijmegen (The Netherlands) creating a series of case studies to investigate contrast-enhance three-dimensional 
power Doppler angiography of the human prostate.
21
  This study likewise explored the subject of ultrasonic 
contrast agents but used human patients instead of an animal model to complete the research.  The overall 
objective of the study was to determine the practicability of contrast-enhanced 3D imaging of the prostate and to 
analyze whether symmetry and distribution of the vascular structures in the 3D images correlated with biopsy 
outcome.
21
 
Eighteen male patients with a strong suspicion of prostate cancer were chosen for the study.  3D power 
Doppler angiography images were obtained in all patients before and after intravenous injection of the contrast 
agent Levovist (2 µm).  All examinations were performed with a Voluson 530 D ultrasound machine with 3D 
capabilities.  Enhancement of power Doppler signals was observed within 1 minute after beginning the contrast 
administration.
21
  After images were obtained, all patients underwent sextant prostate biopsies and specimens 
were color-coded by site of origin and analyzed separately.
21
  
Thirteen cases had positive biopsy results for prostate cancer (72%).
21
  Vascular anatomy was judged abnormal 
in unenhanced images in 6 cases – 5 of which proved malignant.
21
  Enhanced images were considered suspicious 
for malignancy in 12 cases; of these cases, biopsy results found 1 benign vasculature and 11 malignant 
vasculatures.
21
  In 6 patients, B-mode images were considered not suspicious for cancer; however, in 4 of the 6 
patients the final judgment on vasculature was changed from normal to abnormal after administration of the 
contrast agent.
21
  In all these patients, biopsy specimens were found to be malignant.
21
   
Researchers from the study concluded that the use of microbubble contrast agents, such as Levovist, 
combined with 3D imaging gives rise to clear enhancement of Doppler images in the human prostate.
21
  In 11 of 13 
patients with positive biopsies, contrast enhanced images showed abnormal prostate vasculature.  The 
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enhancement of prostatic Doppler images increased the sensitivity from 38% in unenhanced images to 85% in 
enhanced images, a clear sign of the contrast agents’ significance.
21
 
Carpal tunnel syndrome (CTS) is an increasingly prevalent musculoskeletal disorder spanning the globe.  CTS 
presently affects over 8-million Americans and is the number one reported medical problem – accounting for 
about 50% of all work-related injuries.
22
  In relation to the clinical field, carpal tunnel syndrome has been 
discovered to be the most prominent work-related injury among Diagnostic Medical Sonographers.
5
  One study 
found that 90% of sonographers are scanning in pain, with the majority suffering numerous symptoms of CTS.
5
  
Nearly all of the published research regarding carpal tunnel syndrome is targeted at prevention and rehabilitation; 
however, researchers are discovering the diagnostic capabilities of contrast-enhanced ultrasonography (CEUS) in 
identifying and diagnosing CTS.  Additionally, researchers and medical experts praise its potential ability to provide 
a “gold standard” diagnostic tool for the detection of carpal tunnel syndrome.
22
 
In regards of such a novel diagnostic tool, researchers at The Ohio State University developed a study designed 
to provide scientific evidence, gather preclinical safety information, and determine the efficacy of CEUS for 
detection of median nerve vascularity.
13
  The main goal was to identify a contrast media dose that would 
consistently demonstrate perineural vascularity along the median nerve in the macaca fascicularis, and to develop 
a reproducible protocol for sonographically imaging the median nerve along the carpal tunnel inlet.
13 
Eleven young adult female monkeys (macaca fascicularis) were trained to complete a repetitive pinching task 
with their left thumb and finger, mimicking the pre-cursor occupational risks associated with developing carpal 
tunnel syndrome.  During data collection, all subjects were anesthetized with ketamine and maintained with 
isofluorine gas provided from a mask.  The equipment utilized was a GE Logiq 9 (GE Healthcare, Inc., Milwaukee, 
WI) complete with contrast settings and a GE Logiq i (GE Healthcare, Inc., Milwaukee, WI) which is considered a 
hand-carried unit. A 9.0 MHz linear broadband transducer was used with the GE Logiq 9 and a 12.0 MHz linear 
broadband transducer was used with the GE Logiq i hand-carried unit.  Definity® (Lantheus Medical Imaging, 
Billerica, MA) was determinedly used as the contrast agent for the study because it possessed the smallest 
microspheres, 1.1-1.3 um, stability of < 10 minutes, and resonates at 4MHz.
13-16
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Perineural vessels were imaged with a suspension solution of 0.04 mL Definity®/0.96 mL saline introduced 
over five minutes for a total dose of .8 mL of contrast solution.
13
  No side effects or negative reactions were 
documented post-injection of the UCA into the Macaca fascicularis. In order to gather objective data from the 
images collected, the use of an image analysis software program was employed to quantitize the amount of 
perineural vascularity.  In conclusion of the study, researchers both determined the most appropriate ultrasound 
machine settings to image the median nerve of the macaca fascicularis and also developed an appropriate dose of 
the ultrasonic contrast agent (Definity®) to properly visualize the perinueral vasculature for a defined time scale
13
.  
Furthermore, the study found the automated PixelFlux software to be statistically significant in the purpose of 
obtaining objective data in the evaluation of the vascularity of the median nerve.
13
  Researchers concluded the 
article by challenging future CEUS studies to not only determine the reproducibility of their successful imaging 
protocol for the median nerve,  but also to implement a higher level of evidence into such a study.
13
 
Comparative analysis 
All articles similarly concluded that UCAs provide extremely positive effects in sonographic images.
13,16-21
 
In the myocardial opacification study, CEUS allowed for prolonged enhancement of the myocardium along with 
differentiation in the LAD occlusion of the coronary artery.
18
  The early placental study concluded that CEUS allows 
for the determination of intervillous flow in early primate pregnancy, leading to the possibility of a similar analysis 
in human pregnancy.
19
  UCAs provided differentiation between benign and malignant splenic lesions in one canine 
study.
20
  And even more impressive were the results of the human prostate study- CEUS provided a 47% increase 
in the sensitivity of determining benign versus malignant prostate vasculature.
21
  Most innovatively, researchers at 
The Ohio State University developed a protocol for the CEUS imaging of the median nerve and found significant, 
objective measurements with the use of a novel, automated CEUS software.
13
  None of the articles provided 
evidence of negative or null effects of CEUS, significantly showing that contrast-enhanced ultrasound has an 
extremely high rate of positive effects in the demonstrated fields.
13,16-19
  This growing level of evidence should 
provide increased scientific confidence in CEUS and its potential impact on screening for earlier signs of disease.  
13 
 
Also demonstrated within the articles is the importance of microbubble size.
13,16-19
  As scientific evidence 
is increasingly published, the diameter of the ultrasonic contrast agents produced by pharmaceutical 
manufacturers correlationally decrease in size. To further explain, within the animal studies a microbubble size of 
2.5 to 3.8 µm was administered (SonoVue, Perflubutane bubbles, and Albunex, respectively); however, within the 
human study a contrast agent with microbubble size of 2µm was administered (Levovist). Most noteworthy, the 
microbubble size of Definity® within the macaca fascicularis study is of miniscule size; measuring at 1.1-1.3 µm. 
Essentially, research studies such as the ones outlined above show that the smaller the microbubble diameter, the 
more potential the contrast agent has to traverse various body systems and allow for enhancement of images.
16
 
Table 2.1 summarizes the increasingly advanced characteristics of clinically evaluated contrast agents, including 
diameter size.
16
  The advancement of UCA diameter size, along with others seen in the table, provides even more 
possibilities for enhancement in images and diverse applications for screening early stages of disease. 
Agent Physical Components Size (m) Stability Transpulmonary Application 
      
Albunex Air, human albumin 
shell 
3.8 <1 min Yes Endocardial border 
delineation 
Echovist Air, galactose matrix 2 <1 min No Right heart cavities, cardiac 
shunts 
Levovist  Air, galactose matrix 
with palmitic acid 
2 <5 min Yes Heart, liver, kidney imaging 
EchoGen Dodecafluoropentine 2-5 >5 min Yes Cardiac 
Optison Octafluoropropane 2-4.5 >5 min Yes Opacification of heart 
chambers, left ventricular 
endocardial border 
SonoVue Sulfurhexafluoride 
polyethylene glycol, 
phospholipids, 
palmitic acid 
2.5 >5 min Yes Opacificaiton of heart 
chambers; left ventricular 
endocardial border; cerebral, 
carotid, and peripheral 
arteries breast and liver 
vascularity 
Definity Liposome 
encapsulated 
perfluoropropane 
1.1-3.3     <10 min Yes Opacification of heart 
chambers, left ventricular 
endocardial border, prostate 
      
Table 2.1.  Contrast Agent Characteristics. Ultrasound Physics and Instumentation 4
th
 ed.   
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Conclusion 
Overall, the preceding articles offer compelling evidence of UCAs providing enhancement of sonographic 
images.
13,16-19 
 All studies explored various areas of the human anatomy and provided similar, observable 
enhancement of sonography images by means of contrast. Enhancement of images not only assisted in viewing 
complex capillary and musculoskeletal systems within the body, but also helped to identify differences between 
benign and malignant lesions.
13,20
  The fact that using ultrasonic contrast agents has been found to have similar, 
positive opacification effects regarding such a broad range of analyses provides undeniable evidence for the 
diagnostic usefulness of CEUS.  The EFSUMB Guideline also provides an extensive list of anatomical fields, other 
than those in the above articles, that contrast agents can aid in.
17
  Advancements in CEUS, and the continuing 
research regarding UCAs, will only continue to press forward the positive effects found of contrast-enhanced 
ultrasound. Although animal studies are considered a relatively high level of evidence, human trials are necessary 
to promote the benefits of CEUS and ultimately provide the significance necessary for the FDA’s approval of 
diagnostic UCAs in the United States.  
Since the literature is heavily dominated by animal studies that prove the effectiveness of ultrasonic 
contrast agents, a human pilot study that determines the feasibility of utilizing CEUS is necessary to increase the 
levels of evidence in support of UCAs. Given that the researchers at The Ohio State University have concluded an 
immensely successful study, determining not only a protocol for the imaging of the median nerve in macaca 
fascicularis but also the significance of a novel automated software program previously unbeknownst to the U.S. 
medical imaging community, the most appropriate course of action would be to determine the translational 
quality of the study’s results in a human-model. The benefits of the continuation of such a study are trifold – first, 
to provide sufficient background and an increased level of evidence for the FDA’s approval of CEUS, outside of 
echocardiography studies; second, to establish increased verification of the use of contrast-enhanced sonography 
as a diagnostic tool and eventual “gold standard” for identifying  entrapment neuropathy in symptomatic CTS 
patients; and third, to reinforce the success of the retrospective study’s regulatory equipment protocol for imaging 
the median nerve. 
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Research Question 
To address the possibility of CEUS providing diagnostic criteria in association with carpal tunnel syndrome, 
the developed small cohort study ultimately addresses the two following research questions:   
As previously identified within the macaca fascicularis study, is there a quanitifiable vascular difference in the 
median nerve in CTS symptomatic humans versus CTS asymptomatic humans?  Furthermore, are the identified 
protocol and equipment settings optimal to capture consistent and replicable CEUS images along the course of 
the human median nerve while simultaneously providing little to no risk for patient well-being?  
 By investigating these research questions, valuable information may be attained that will increase the 
knowledge and support of the identification and evaluation of CTS by use of CEUS. 
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Chapter 3 – Methods and Analysis 
 The following materials and methods were determined by the published materials and methods defined 
in a retrospective study conducted by researchers at The Ohio State University.  A detailed description of the 
following materials and methods have been published in a referenced article and comparatively used for this 
research study.
13 
Materials and Methods 
 
Patients  
This study was designed to obtain a higher level of clinical information, verify the effectiveness of 
equipment settings determined in a retrospective CEUS study, and determine the efficacy of CEUS for detection of 
median nerve vascularity in a human-model. Nine human patients from The Ohio State University Wexner Medical 
Center (OSUWMC) were voluntarily recruited to participate in the musculoskeletal CEUS study alongside their 
originally scheduled CEUS echocardiography studies.  The subjects were briefed about the purpose and associated 
risk of the study and properly directed to sign the appropriate consent forms required by The Ohio State 
University’s (OSU’s) Internal Review Board (IRB). The subjects varied in age, gender, and symptomatic or 
asymptomatic syndromes of the wrist, hand, and fingers.  Individuals were excluded from the study if the  
participant had major trauma in the distal upper extremity, the participant had previous carpal tunnel surgery in 
the right hand, the participant was previously diagnosed with polyneuropathy, the participant had a dialysis shunt 
in the right upper extremity, or if the participant was pregnant or within 3 months post-partum.  Physical 
examinations and pain-severity surveys were completed before the sonographic imaging proceeded. Evaluations 
were performed at Ohio State’s Ross Heart Hospital – Noninvasive Peripheral Vascular Laboratory in Columbus, 
OH.  Vital signs and adverse reactions were monitored by a registered nurse employed by OSUMC.  The research 
study was granted approval by OSU’s Internal Review Board. 
 
Equipment  
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The equipment utilized was a GE Logiq i, which is considered a hand-carried unit.  A 12.0 MHz linear 
broadband transducer, downshifted to a transmit frequency of 9.0 MHZ, was consistently used to examine the 
median nerve of the patient. The output power was reduced to 4% in order to preserve the contrast activity. 
Throughout the series of experiments, quality control was maintained on the units and transducers with weekly 
checks based on imaging of the tissue mimicking phantom.  
Previously determined equipment settings, as outlined in an earlier published study, were maintained to 
record consistent imaging data of the human median nerve.  At the end of each CEUS session, the output power 
was increased to 100% for one minute to clear any residual contrast and a saline flush was also applied.  
 
Contrast dosing  
Definity®
23
 was used as the contrast agent for this study because it possesses the smallest microspheres, 
1.1-1.3 um, stability of < 10 minutes, and resonates at 4MHz.
16
  These unique features of Definity® made it ideal 
for this experimental application. The dosing protocol was developed in consultation with the manufacturer and 
with cardiac sonographers who had experience using the product for human studies.  A registered nurse employed 
by OSUMC managed the preparation of the doses designed to increase visualization of selective anatomical 
structures. The contrast was activated according to the instructions provided by the manufacturer and was also 
vigorously agitated in the syringes prior to being injected.
23 
  A work-sheet was kept that contained quantitative 
and qualitative data relating to the injection of contrast for each session and subject.  Each subject had a 20-gauge 
catheter placed in either the right antecubital area or back of the right hand.  The number of injections and 
contrast dosing amounts varied by patient, and were at the discretion of the lead echocardiography sonographer. 
Nine subjects were imaged with a series of random injections as determined by the lead 
echocardiography sonographer. Research sonographers (AMH, KDE, & KRV) were blinded to the dosing series and 
the injections were concealed so that all immediate CEUS data was collected and evaluated without knowledge of 
the injection type or the order they were administered. This subset of experiments was added to confirm the rigor 
and reliability of the results that were reported.  
 
CEUS image analysis  
18 
 
The equipment settings were maintained as outlined in a previously determined imaging protocol of a 
CEUS study of the median nerve.  Additionally, a multi-incremental sampling method for imaging was similarly 
preserved. The imaging samples were captured at baseline and then every 30 seconds until seven minutes elapsed 
from the initial injection.  
In the original study, choices were limited as to the method for image analysis given the restrictions 
imposed by the United States’ FDA on the use of CEUS. Given this situation, a manual system was chosen for the 
pre-clinical study and maintained in the human study for assessing enhanced vascularity around the median nerve. 
To accomplish this, manual counting of PD pixels on the multi-incremental images, captured throughout the series 
of imaging trials, was conducted. The Klauser method
2
 for counting PD pixels within the region of interest (ROI) 
was also maintained in the prospective study.  
 
Statistical Analysis  
Descriptive data was collected during the equipment optimizing trials as well as logs of equipment set up.  
These were used to record settings and resulting subjective image quality.  Descriptive data was also charted on 
injection quantity, contrast activity beginning and ending times, and subject physiologic response.  The final images 
of the respective median nerves were analyzed with a manual method and the resultant data was recorded for 
future analysis. Due to the manual method chosen to assess the data, measures of agreement and reliability were 
completed to verify the intra-rater reliability of the author of this study (AMH) in comparison to the original study’s 
researchers (KDE & KRV).  The information gleaned from the Pixel Flux Scientific software provided the foundation 
for the subjective and qualitative analysis of the recorded images.  The image data was evaluated within subjects 
and over the intermittent time of imaging; specific research numbers were then recorded for further data analysis 
and are detailed in the following chapter.  
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Chapter 4 – Results 
Demographics 
 The subject cohort consisted of 9 individuals (9 male, 100.00%).  Symptoms were reported in 4 subjects 
(44.4% prevalence).  Subject age ranged from 47-77 years (mean age, 62 ± 15 years) at the time of examination.  
All nine subjects were imaged with CEUS to determine the vascularity associated with the median nerve.  The 
imaging parameters remained constant throughout the examination for all subjects while contrast dosing varied.  
Although some reactions have been associated with the use of Definity® as the contrast agent used for cardiac 
imaging, our subjects exhibited no reactions and tolerated multiple injections of the UCA without incident. 
 
CEUS imaging technique  
 The subject trials were completed to consistently image CEUS of the median nerve at the carpal tunnel 
inlet and validate the imaging technique previously determined in the referenced Macaque study.  The contrast 
dosing amounts were determined at the discretion of the lead sonographer, as previously noted, and varied in 
both dosing amount and number of dosing injections.  The contrast dosing amounts varied from 3 ml (Patient 1) to 
5 ml (Patient 5), with a mean dose of 3.33 ml over all patients.  The contrast dosing solution for all subjects 
contained 1.3 ml of Definity® to 8.7 ml of saline.  In addition, the equipment parameters were maintained at 4% 
output power and a mechanical index (MI) of 0.13.  The transmit frequency of the linear transducer was held at a 
constant of 9 MHz throughout the trials.  
 
Dosing trials  
Two syringes were drawn up; one contained a suspension solution of 1.3 ml of Definity®- perflutren lipid 
microspheres to 8.7 mL saline and a second contained a saline solution, designated as a post-examination flush. All 
injections were introduced via a venous catheter at the antecubital space or behind the patient’s right hand.  
Examinations began with an initial contrast injection at 0 seconds and were followed by booster injections of 
various amounts and times at the discretion of the main echo sonographer.  All dosing trials were followed by a 
saline flush of the venous catheter by the attending OSUWMC nurse.  
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The descriptive results for recording the median start time in detecting CEUS perivascular flow of the 
median nerve, was 30 seconds after the primary injection of contrast was given. All nine of the subjects were 
imaged over 7 minutes to detect the vascularity within the median nerve. The subjective start time for detecting 
Definity® within the median nerve was 30 seconds for the 9 trials. The subjective time of enhanced detection of 
vascularity was between 30 seconds to 2 minutes post-contrast injection. The subjective extent of vascular filling 
was minute but still evident at the end of the 7 minute imaging trial.  
 
Measurement Reliability  
The author of this study (AMH) completed an individual, blinded analysis using Pixel Flux® to evaluate 
inter-rater reliability with the investigators of the original CEUS preclinical study study (KDE & KRV). The first 5 
animal-subjects that received Definity® were analyzed by all investigators at each 30 second incremental frame 
between 00:00 min to 07:00 mins. Investigators individually drew a manual ROI around the median nerve within 
which contrast pixels were counted and evaluated for intensity. Each examiner evaluated 15 frames for a pixel 
count and recorded the average and maximum intensity within ROI as calculated by the software. Inter-rater 
reliability was determined between the investigators for manual signal counts and Iavg within the ROI using 
Chronbach’s alpha and ICC.  Chronbach’s alpha for signal counts and Iavg were 0.90 and 0.80 and ICCs were 0.90 
(p< 0.01) and 0.80 (p<0.01), respectively.  
 
CEUS Kinetics  
With high reliability established, descriptive and comparative data analyses were completed based on the 
evaluation of images across 15 time points in the 9 human subjects (n=135 images). The mean for pixel count 
across all subjects and all time points was 7.97 (SD, 11.50) pixels.  In further statistical comparison, asymptomatic 
patients’ pixel counts averaged 4.01 (SD, 3.27) pixels and varied between 1 pixels per image to 17 pixels per image; 
whereas symptomatic patients’ pixel counts averaged 12.85 (SD, 15.52) pixels and varied between 1 pixels per 
image to 78 pixels per image.  
To correlate the research results with similar CEUS studies being performed in European and East Asian 
countries, the Klauser method of counting perfusion intensities was also used.  This categorical method is based on 
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a scale of correlating perfusion intensity to an ordered ranking, on a scale from 0 (least intense) to 3 (most 
intense).  In analysis of the data, the Klauser method
24
 determined the mean perfusion intensity for asymptomatic 
patients to be 1.18 (SD, 0.58) pixels and symptomatic patients to be 1.83 (SD, 0.86) pixels.  Further explanation of 
the Klauser method
24
 and how it is correlated to this study is demonstrated in Tables 4.1 and 4.2.  
 
Grade Key Pixel Count 
0 0 
1 1-5 
2 6-10 
3 >11 
 
Table 4.1. The Klauser method
24
 for perfusion intensity. 
 
 Pixel Count  
Mean 
Klauser Method Mean 
Subject 1 * 27.2 2.40 
Subject 2 3.87 1.20 
Subject 3 2.34 0.86 
Subject 4 * 12.4 2.07 
Subject 5 5.87 1.53 
Subject 6 5.93 1.40 
Subject 7 * 6.53 1.67 
Subject 8 1.93 0.87 
Subject 9 * 5.26 1.40 
   
Asymptomatic Overall 4.01 1.17 
Symptomatic Overall 12.85 1.89 
 
Table 4.2. Mean pixel count and mean Klauser
24
 scores per patient. 
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Chapter 5 – Discussion 
 
 Within the past decade, research has provided compelling evidence that sonography may be used as a 
first-line diagnostic tool for the identification and evaluation of CTS.
13,17-21
  The purpose of this study was to explore 
the ability of CEUS to determine minute yet quantifiable vascular differences in the periphery of the asymptomatic 
vs. symptomatic median nerve. Additionally, this research sought to confirm the reproducibility of previously 
published sonographic parameters for imaging and evaluating the median nerve.  
 
Clinical translation 
 The foundation of this research revolved around the successful transition from a pre-clinical study to a 
clinical cohort study.  Previous literature
5
 provided significant evidence in a study of eleven macaca fasciculari that 
detection of hypervascularity in the median nerve of monkeys with CTS-like symptoms could be detected by CEUS.  
The successful translation of previously identified imaging protocol and sonographic equipment settings achieved 
by this subsequent study provides further support for the ability of CEUS to detect perineural vascularity.   
 It is important to note that an immense strength of this study is founded on the basis of patients’ 
tolerance to the contrast agent Definity®.  No UCA reactions were documented in the preclinical model nor 
demonstrated within the human cohort.  Contrast safety is of utmost importance to not only  the demonstration of 
quality patient care within the clinical field, but also to the establishment of CEUS as a diagnostic tool recognized 
and approved by the FDA. As outlined specifically within the Food and Drug Administration Safety and Innovation 
Act (FDASIA), novel medical tests and devices must provide definitive safety and protection for patients before 
clinical implementation for medical use.
25
 
This study ultimately sets the stage for further investigation of perineural vascularity – the 
accomplishment of translating a preclinical model to clinical model without risk to patient well-being adds an 
undeniable level of evidence to the prospect of CEUS becoming a first-line diagnostic tool for the detection of CTS.   
 
Reliability 
23 
 
 The strength of this study is based upon the blinded, individual measurement analysis completed to 
establish an inter-rater reliability with the use of the novel software Pixel Flux.  The importance of reliable 
objective measurements within a team of medical researchers is essential for the dependability of translating 
perfusion measurement from research to clinical practice. As advanced medical software such as Pixel Flux is 
increasingly implemented into ultrasound exams, and the possible groundwork for neural vascularity detection as 
proposed by this research, there is a need for a direct measure of reliability and reproducibility in a group of 
sonographers conducting a CEUS within a clinical lab.   
 
Research variables 
 One central variable was evaluated to assess the hypervascularity of the median nerve in clinical patients:  
the ability of contrast-enhanced ultrasound to image tissue perfusion of the median nerve.  This variable was 
analyzed using a designated protocol referenced in earlier published literature, and a manual method for counting 
PD pixels by use of the novel tissue perfusion software Pixel Flux.  Two counting methods were used to examine 
the ability of CEUS to detect vascular changes in the median nerve- Individual pixel counts and their respective 
means, as well as the Klauser method.
24
  
 Following qualitative analysis of the pixel counts in all asymptomatic and symptomatic patients’ images, 
two conclusions were revealed. First, there in fact appears to be a successful differentiation in the vascularity of 
the median nerves by subjective pixel counts alone. As outlined with further detail in Table 2, the overall mean for 
asymptomatic patients was 4.01 pixels per image; whereas, the overall mean for symptomatic patients was 12.85 
pixels per image.  This increase in pixels per image from asymptomatic to symptomatic patients provides pre-
imaging evidence of CEUS having the ability to determine minute vascular changes in CTS affected patients.  The 
perfusion data provides further verification that as clinical symptoms and the pathophysiology of CTS manifests, an 
increase in vascularity occurs.  This increase in vascularity can then be detected by CEUS, and ultimately is 
translated to a higher overall mean in the pixel counts for the symptomatic patient when using a semi-automatic 
software to analyze the images.   In further qualitative analysis, it is important to note that while asymptomatic 
patients’ pixel counts varied from only 1 to 17 pixels per image, symptomatic patients’ pixel counts varied from a 
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vast 1 to 72 pixels per image. This increase in the variation of pixel count amounts also adds substantial evidence 
supporting the ability of CEUS to detect minuscule vascularity changes in the median nerve. 
However, the second conclusion was that the Klauser method
24
 of scoring pixel intensities appears to 
ineffectively represent the minute vascular changes that occur in asymptomatic vs. symptomatic median nerves. 
While the subjective pixel counts are notable, their respective rankings among the Klauser scale are less than 
impressive (see Figure 2).  This result concurs with previous literature and similarly challenges the use of 
categorical scoring of CEUS for accurately categorizing the minute changes in vascularity within symptomatic 
median nerves
13
. The lack of correlation between subjectively counting pixels and ranking intensities into 
categories indicates the need for continued work to determine which measurement method is most 
representative of perineural vascularity.
13
   
 Sonography and its subcategory of CEUS have presented as an exciting and novel diagnostic test for the 
diagnosis of carpal tunnel syndrome.  Advantages of sonography as a first-line diagnostic test for CTS include wide 
availability, cost-efficiency, portability, and high tolerance by patients.  Recent literature has concluded that the 
benefits and reliability of sonography in the detection and diagnosis of CTS are growing exponentially. As stated 
earlier, it is entirely plausible that with increasing levels of evidence and data from research trials – such as the one 
described here – sonography may replace EDX as a first-line test to confirm clinically diagnosed CTS, and 
potentially provide for a “gold standard” in carpel tunnel syndrome diagnosis. 
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Chapter 6 – Conclusion 
 While the initial research results seem promising, due to the current restrictions on the use of CEUS as 
imposed by the US Food and Drug administration, this small cohort study inherently encountered several 
limitations.  The most notable of these limitations is the small sample size. Due to the official patient count 
concluding at nine human subjects, the results obtained within this research study cannot be generalized to larger 
populations.  Additionally, because subjects were recruited to the study out of convenience and on a volunteer 
basis, the results lack random assignment and subsequent generalizability to the public.  Prospective research 
studies with increased recruitment and randomization are necessary to determine the clinical significance and 
prospect of CEUS becoming a preferred diagnostic test for evaluating carpal tunnel syndrome. 
 Inability to maintain controlled variables was another intrinsic limitation.  Due to federal restrictions, 
researchers were unable to define a control dosing of the contrast agent Definity®.  Amounts of the contrast 
injection varied per personal preference of the main sonographer performing the echocardiogram.  This lack of 
consistency fails to identify a contrast media dose that would consistently demonstrate perineural vascularity 
along the human median nerve. Continued research is necessary to provide a resolute and reliable contrast dose 
to consistently image the minute vascularity of the median nerve.  
 Missing parameter values was another significant limitation to this cohort study, potentially causing an 
under-estimation of patient symptom severity and asymptomatic pixel counts.  One symptomatic patient did not 
complete the full symptom severity evaluation, and parameters used to score his pain levels were missed. While 
this missing information did not hinder this particular study, future studies will need to evaluate the correlation 
between symptom severity and pixel perfusion. Additionally, pixel counts were missing in one symptomatic 
patient’s sample increment at 0:30 minutes. Patient error was to blame as he moved his wrist during the image 
sampling and caused that specific image timeframe to be missed.  
 Finally, the research productively supports the utilization of CEUS for evaluating the vascularity of the 
median nerve in asymptomatic versus symptomatic CTS patients.  Despite the inherent limitations, the research 
provides increasing levels of evidence for the prospective use of CEUS for the detection and evaluation of CTS and 
its associated hypervascularity of the median nerve.  The use of perfusion software to subjectively detect increased 
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vascularity provides a promising foundation for the quantified measurement of median nerve hypervascularity.  
However, the discovered lack of sensitivity in the Klauser method of categorical scoring signifies the need for 
continued work to determine a measurement method that accurately represents minute changes in perineural 
vascularity.  One of the most important discoveries of this study relies on the fact that no UCA reactions were 
documented in the preclinical model nor demonstrated within the human cohort.  As stated previously, contrast 
safety is of utmost importance to the establishment of CEUS as a diagnostic tool recognized and approved by the 
FDA.  Given that this novel diagnostic tool has no risk to patient well-being, it can be established as an extremely 
safe exam for the evaluation of human median nerves.  
Finally, the results of this study encourage continued research into the most consistent and valid 
techniques for evaluating entrapment neuropathy, and offers increasing levels of evidence for the use of CEUS as a 
primary diagnostic tool for CTS. The potential benefits of CEUS are limitless, and more research is encouraged for 
continued validation of CEUS as an invaluable diagnostic tool to the medical community 
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List of Abbreviations 
 
CEUS Contrast-enhanced ultrasound 
CSA Cross-sectional area 
CT Computed tomography 
CTS Carpal tunnel syndrome 
DMS Diagnostic medical sonography 
EDX Electrodiagnostic testing 
EFSUMB 
European Federation of Societies for Ultrasound in 
Medicine and Biology 
EMG Electromyogram 
FDA Food and Drug Administration 
FSS Functional status scale 
IRB Institutional review board 
MI Mechanical index 
MRI Magnetic resonance imaging 
NCS Nerve conduction study 
OSU The Ohio State University 
OSUWMC The Ohio State University Wexner Medical Center 
ROI Region of interest 
SD Standard deviation 
SSS Symptom severity scale 
UCA Ultrasonic contrast agent 
2 
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Patient Screening and Chart Review
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Symptom Severity Assessment 
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Sonographic Images:  Pixel Flux Evaluation of the Human Median Nerve 
Asymptomatic Patient 
 
 
0:00 minutes, pre-injection 
 
 
2:00 minutes, post-injection 
 
No increased vascularity noted in the asymptomatic median nerve 
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Sonographic Images:  Pixel Flux Evaluation of the Human Median Nerve 
Symptomatic Patient 
 
 
0:00 minutes, pre-injection 
 
 
2:00 minutes, post-injection 
 
The contrast agent, Definity®, acts as a catalyst for sonograhpic sensitivity and enhances the hypervascularity of 
the symptomatic median nerve. 
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Sonographic Images:  Comparison of asymptomatic vs. symptomatic patients 
 
 
Asymptomatic patient. 2:00 minutes, post-injection. 
 
 
Symptomatic patient. 2:00 minutes, post-injection 
 
Hypervascularity is readily visualized in the symptomatic patient following injection of the contrast agent Definity®. 
The asymptomatic patient shows no increased vascularity post-injection, confirming the physiologic 
pathophysiology of CTS. 
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